

## Livalo<sup>®</sup> (pitavastatin) – First-time generic

- On November 2, 2023, <u>Teva launched</u> an AB-rated generic version of Eli Lilly and Kowa Pharmaceuticals' <u>Livalo (pitavastatin)</u> tablets.
  - Other AB-rated approved generics for Livalo include <u>Aurobindo</u>, <u>Mylan/Viatris</u>, <u>Orient</u>, <u>Sawai</u>, and <u>Zydus</u>. Launch is pending for these generics.
- Livalo is approved as an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia and adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia.
- Pitavastatin is also available as brand **Zypitamag** tablets.
  - Zypitamag is approved as an adjunctive therapy to diet in adult patients with primary hyperlipidemia or mixed dyslipidemia to reduce elevated total cholesterol, LDL-C, apolipoprotein B, triglycerides, and to increase high-density lipoprotein cholesterol.
  - Zypitamag is not approved for pediatric use because of marketing exclusivity rights.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews<sup>®</sup> is published by the Optum Rx Clinical Services Department.